Summary & Overview
HCPCS Q4315: Regenelink Amniotic Membrane Allograft, Per sq cm
HCPCS Level II code Q4315 designates Regenelink amniotic membrane allograft billed per square centimeter as an add-on to a primary procedure. This biologic allograft is used in wound care and tissue repair, with growing clinical adoption as a treatment adjunct for complex or non-healing wounds. The code matters nationally because it standardizes reporting for product-based grafts, supports consistent billing across outpatient surgical and wound care settings, and informs payer coverage and reimbursement policy decisions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, typical sites of service, and payer landscape. The publication outlines expected benchmarks for use and reimbursement, summarizes relevant policy considerations and prior authorization trends, and highlights implications for coding practice when Q4315 is billed as an add-on item to a primary procedure. Practical guidance on documentation expectations and common billing scenarios is provided to clarify when the product is reported separately versus bundled.
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, detailed payer fee schedules, and related codes.
Billing Code Overview
HCPCS Level II code Q4315 represents Regenelink amniotic membrane allograft, billed per square centimeter. This code is an add-on, list separately in addition to primary procedure and describes a biologic allograft product used in wound care and tissue repair.
Service Type: Amniotic membrane allograft application / biologic graft product
Typical Site of Service: Outpatient surgical facilities, hospital outpatient departments, ambulatory surgery centers, and clinic-based wound care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a chronic, non-healing lower extremity ulcer (commonly diabetic foot ulcer or venous stasis ulcer) presents to a wound care clinic after standard wound care and offloading have failed. After evaluation including debridement, infection control, vascular assessment, and optimization of comorbidities, the provider elects to apply an amniotic membrane allograft product. The product billed with Q4315 (Regenelink amniotic membrane allograft, per square centimeter) is used as an adjunctive biologic graft placed directly on the prepared wound bed to promote healing. Typical workflow: initial wound assessment and measurements; procedural informed consent; sharp/pulsed lavage debridement; hemostasis and wound bed preparation; measurement of square centimeters of graft material used; application and securement of the allograft (may include sutures, tissue adhesive, or secondary dressing); dressing change instructions and scheduled follow-up visits for assessment and potential reapplication. Typical site of service includes outpatient wound care centers, physician offices (dermatology, podiatry), ambulatory surgical centers, and hospital outpatient departments. Common clinical indications include chronic diabetic ulcers, venous stasis ulcers, arterial ischemic ulcers after revascularization, and complex surgical wounds requiring biologic coverage. Evaluation and management, debridement, graft application, and wound care supplies are billed separately; Q4315 is an add-on, reported per square centimeter in addition to the primary procedure or visit charges.
Coding Specifications
| Modifier | Description | When to Use |
|---|